Clayton Russell
Chief Medical Officer
Clayton Russell has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Nov 18, 2026.
On the most recent filing, Clayton Russell is listed as Chief Medical Officer at Larimar Therapeutics, Inc. Inside the rolling window, Clayton Russell reported 1 open-market purchase totaling $10K in LRMR and no open-market sales.
Companies traded
Other insiders at LRMR
Insider Buying
$10K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Clayton Russell made?
Clayton Russell has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Clayton Russell trade?
Clayton Russell has filed SEC Form 4 disclosures for 1 company, including LRMR.
When was Clayton Russell's most recent SEC Form 4 filing?
Clayton Russell's most recent SEC Form 4 filing on Tracefour is dated Nov 18, 2026.
What is Clayton Russell's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Clayton Russell is listed as Chief Medical Officer.
What is Clayton Russell's total buy and sell value in the current window?
Inside the rolling retention window, Clayton Russell bought $10K and sold $0 based on SEC Form 4 filings.
What was Clayton Russell's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 3,322 LRMR shares on 2026-11-16, worth $10K, per SEC Form 4 filings.